Aevice Health vs BillionToOne
Side-by-side comparison of AI visibility scores, market position, and capabilities
Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that continuously tracks wheezing, coughing, and breathing abnormalities in asthma and COPD patients.
About
Aevice Health develops wearable respiratory monitoring technology that uses AI to analyze breath sounds captured continuously from a chest-worn device. The AeviceMD system detects wheezing, coughing, and abnormal breathing patterns in real time, enabling early warning of asthma attacks and COPD exacerbations before they require emergency care. The device transmits data to a smartphone app and clinical dashboard for remote monitoring by pulmonologists.
IPO Nov 2025 (BLLN, Nasdaq); $273M raised; 508K+ tests in 2025; $293–299M revenue guidance FY2025.
About
BillionToOne is a leading molecular diagnostics company that has commercialized a proprietary technology platform—Quantitative Counting Templates (QCTs)—enabling detection and quantification of disease-related DNA at single base-pair resolution. This breakthrough in cell-free DNA (cfDNA) analysis underpins its two primary product lines: UNITY Screen for comprehensive prenatal genetic screening (covering carrier status, chromosomal conditions, and fetal risk) and Northstar Select for oncology therapy guidance and liquid biopsy.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.